Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia - Logunov, D Y; Dolzhikova, I V; Zubkova, O V; Tukhvatullin, A I; Shcheblyakov, D V; Dzharullaeva, A S (Lancet, 2020)
(10255):